相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia
Ing S. Tiong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
Miguel-Angel Perales et al.
HAEMATOLOGICA (2020)
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon et al.
INVESTIGATIONAL NEW DRUGS (2020)
Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT
Maria H. Gilleece et al.
LEUKEMIA (2020)
Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission
Takaaki Konuma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Acute myeloid leukaemia and the immune system: implications for immunotherapy
A. John Barrett
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis
Vincent T. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Xin He et al.
BLOOD (2020)
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting
Amanda C. Przespolewski et al.
BLOOD REVIEWS (2020)
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Alexandros Spyridonidis et al.
BONE MARROW TRANSPLANTATION (2020)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
Anne Sophie Kubasch et al.
LEUKEMIA (2020)
ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
Denis Claude Roy et al.
LEUKEMIA (2020)
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Elihu Estey et al.
LEUKEMIA (2020)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Clonal competition within complex evolutionary hierarchies shapes AML over time
Carl Sanden et al.
NATURE COMMUNICATIONS (2020)
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Rebecca Epperly et al.
FRONTIERS IN ONCOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ali Bazarbachi et al.
HAEMATOLOGICA (2020)
Neoantigens in Hematologic Malignancies
Melinda A. Biernacki et al.
FRONTIERS IN IMMUNOLOGY (2020)
T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
Valerie Janelle et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Olaf Penack et al.
Lancet Haematology (2020)
T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources
Sarah Bonte et al.
ONCOIMMUNOLOGY (2020)
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells
Renier Myburgh et al.
LEUKEMIA (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Heuser et al.
ANNALS OF ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
David Vetrie et al.
NATURE REVIEWS CANCER (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
Darren Pan et al.
BLOOD ADVANCES (2020)
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
Oscar Bruck et al.
BLOOD ADVANCES (2020)
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia
Haydar Celik et al.
BLOOD ADVANCES (2020)
Efficacy of combined CDK9/13ET inhibition in preclinical models of MLL-rearranged acute leukemia
Hannah McCalmont et al.
BLOOD ADVANCES (2020)
Clinical and functional significance of circular RNAs in cytogenetically normal AML
Dimitrios Papaioannou et al.
BLOOD ADVANCES (2020)
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
Jyoti Naik et al.
HAEMATOLOGICA (2019)
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation
Remy Dulery et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2019)
Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
Jong Bok Lee et al.
BLOOD REVIEWS (2019)
Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled
Jan Philipp Bewersdorf et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Haematopoietic stem cell activity and interactions with the niche
Sandra Pinho et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
Maddalena Noviello et al.
NATURE COMMUNICATIONS (2019)
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
Amanda McBride et al.
FRONTIERS IN ONCOLOGY (2019)
Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail
Joseph E. Maakaron et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Novel monoclonal antibody-based therapies for acute myeloid leukemia
Linde M. Morsink et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Venetoclax-based therapies for acute myeloid leukemia
Veronica A. Guerra et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia
Michael R. Savona et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment
Toshiki Terao et al.
CELLS (2019)
Availability of FLT3 inhibitors: how do we use them?
Alexander E. Perl
BLOOD (2019)
Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission
Shingo Yano et al.
BONE MARROW TRANSPLANTATION (2019)
Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy
Pankaj Kumar et al.
IMMUNOTHERAPY (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Aude G. Chapuis et al.
NATURE MEDICINE (2019)
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
Rupa Narayan et al.
PLOS ONE (2019)
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease
Jesper Falkesgaard Hojen et al.
NATURE IMMUNOLOGY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa et al.
CANCERS (2019)
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
Yufeng Shang et al.
FRONTIERS IN ONCOLOGY (2019)
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Andrew H. Wei et al.
BLOOD (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
A. E. Perl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers A Systematic Review and Meta-analysis
Nico Gagelmann et al.
JAMA ONCOLOGY (2019)
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
Lourdes M. Mendez et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells
Walid Warda et al.
CANCER RESEARCH (2019)
How close are we to CAR T-cell therapy for AML?
Saar Gill
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia
Frederick R. Appelbaum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naval G. Daver et al.
BLOOD (2019)
Cell-Extrinsic Stressors from the Aging Bone Marrow (BM) Microenvironment Promote Dnmt3a-Mutant Clonal Hematopoiesis
Jennifer Myers SanMiguel et al.
BLOOD (2019)
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
Beatrice Drexler et al.
HAEMATOLOGICA (2019)
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
Dyantha van der Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Malte Roerden et al.
FRONTIERS IN IMMUNOLOGY (2019)
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
Celalettin Ustun et al.
BLOOD ADVANCES (2019)
The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models
James Neil Fisher et al.
HEMASPHERE (2019)
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
Jorge Garcia Borrega et al.
HEMASPHERE (2019)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
How to say NO to vascular disruption and stem cell mobilization
Diana Passaro et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype
Saisai Li et al.
HUMAN GENE THERAPY (2018)
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
Nathaniel J. Buteyn et al.
INTERNATIONAL IMMUNOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IL1RAP potentiates multiple oncogenic signaling pathways in AML
Kelly Mitchell et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
Jessica C. Petrov et al.
LEUKEMIA (2018)
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
Mona M. Hosseini et al.
LEUKEMIA (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Na Luo et al.
NATURE COMMUNICATIONS (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore et al.
HAEMATOLOGICA (2018)
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
Ansu Abu Alex et al.
FRONTIERS IN IMMUNOLOGY (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions
Christian M. Schurch
FRONTIERS IN ONCOLOGY (2018)
Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity
Adam J. Lamble et al.
FRONTIERS IN ONCOLOGY (2018)
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission
Francesca Lorentino et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Lorenzo Brunetti et al.
CANCER CELL (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack
Richard F. Schlenk et al.
HAEMATOLOGICA (2018)
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
Todd A. Braciak et al.
ONCOIMMUNOLOGY (2018)
Acute myeloid leukemia: 2019 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann et al.
BLOOD (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Noncoding regions are the main source of targetable tumor-specific antigens
Celine M. Laumont et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
Lucas Gutierrez et al.
SCIENTIFIC REPORTS (2018)
Clinical consequences of clonal hematopoiesis of indeterminate potential
David P. Steensma
BLOOD ADVANCES (2018)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial
Andreas Burchert et al.
BLOOD (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2018)
Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia
Eben Lichtman et al.
BLOOD (2018)
IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia
Hong Mu et al.
BLOOD (2018)
Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial
Adrian F. Ochsenbein et al.
BLOOD (2018)
Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Betul Oran et al.
BLOOD (2018)
Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Rachel J. Cook et al.
BLOOD (2018)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Naval G. Daver et al.
BLOOD (2018)
Single-Cell Sequencing in Normal and Malignant Hematopoiesis
Nicola K. Wilson et al.
HEMASPHERE (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse
Robson G. Dossa et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Lars Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2017)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts
G. Garcia-Manero et al.
LEUKEMIA (2017)
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
Silvia Arcangeli et al.
MOLECULAR THERAPY (2017)
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Haruko Tashiro et al.
MOLECULAR THERAPY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
Victor Prima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Michael R. McKeown et al.
CANCER DISCOVERY (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
Andrew H. Wei et al.
BLOOD (2017)
Gemtuzumab ozogamicin for acute myeloid leukemia
Frederick R. Appelbaum et al.
BLOOD (2017)
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Charles F. Craddock et al.
CLINICAL CANCER RESEARCH (2017)
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS
Isao Tawara et al.
BLOOD (2017)
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
Sebastien Anguille et al.
BLOOD (2017)
Inflammation: a key regulator of hematopoietic stem cell fate in health and disease
Eric M. Pietras
BLOOD (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia
Diana Passaro et al.
CANCER CELL (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Rebecca Warfvinge et al.
BLOOD (2017)
Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia
Colin D. Godwin et al.
BLOOD (2017)
The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications
Hind Medyouf
BLOOD (2017)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Lowenberg et al.
BLOOD (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo
Caroline Pabst et al.
BLOOD (2016)
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
Helena Agerstam et al.
BLOOD (2016)
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients
J. Fucikova et al.
BLOOD (2016)
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy
Ruxanda Moschoi et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
Haobin Ye et al.
CELL STEM CELL (2016)
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage
Lynn Quek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses
Colleen M. Lau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Helena Boutzen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+delineate FLT3/ITD-positive clones
Adhra Al-Mawali et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers
D. P. Granados et al.
LEUKEMIA (2016)
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
A. Chaturvedi et al.
LEUKEMIA (2016)
Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal
Eric M. Pietras et al.
NATURE CELL BIOLOGY (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
Radhika Thokala et al.
PLOS ONE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Norbert Vey et al.
ONCOTARGET (2016)
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
George S. Laszlo et al.
ONCOTARGET (2016)
Mutations in AML: prognostic and therapeutic implications
Courtney D. DiNardo et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)
Eunice S. Wang et al.
BLOOD (2016)
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Guillermo Garcia-Manero et al.
BLOOD (2016)
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
Masayuki Iwasaki et al.
CELL STEM CELL (2015)
Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT
Salyka Sengsayadeth et al.
HAEMATOLOGICA (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Helena Agerstam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT
Salyka Sengsayadeth et al.
HAEMATOLOGICA (2015)
AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts
Nandini Rudra-Ganguly et al.
BLOOD (2015)
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
Boglarka Gyurkocza et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
T. Ruutu et al.
BONE MARROW TRANSPLANTATION (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Evolution of the Cancer Stem Cell Model
Antonija Kreso et al.
CELL STEM CELL (2014)
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Lev M. Kats et al.
CELL STEM CELL (2014)
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
James O. J. Davies et al.
CYTOTHERAPY (2014)
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment
Holger Kroenig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells
R. Klar et al.
LEUKEMIA (2014)
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
M. Ryan Corces-Zimmerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides
Diana Paola Granados et al.
NATURE COMMUNICATIONS (2014)
Fatty acids, lipid mediators, and T-cell function
Anja J. de Jong et al.
FRONTIERS IN IMMUNOLOGY (2014)
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AMLStudy Group (AMLSG)
Peter Paschka et al.
BLOOD (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Maria Askmyr et al.
BLOOD (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
How I assess comorbidities before hematopoietic cell transplantation
Mohamed L. Sorror
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Myeloid leukemia cells with a B7-2+ subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands
Yusuf Dolen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations
Jonathan M. Gerber et al.
ONCOTARGET (2013)
CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes
Stephen S. Chung et al.
BLOOD (2013)
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
Stefani Spranger et al.
BLOOD (2012)
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Laura Barreyro et al.
BLOOD (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
John S. Welch et al.
CELL (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Nicolas Goardon et al.
CANCER CELL (2011)
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10
M. C. Bene et al.
LEUKEMIA (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
R. Majeti
ONCOGENE (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Yoshikane Kikushige et al.
CELL STEM CELL (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
Rifca Le Dieu et al.
BLOOD (2009)
Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines
Matthias Schaefer et al.
CANCER RESEARCH (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
Liqing Jin et al.
CELL STEM CELL (2009)
Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia
Miroslaw J. Szczepanski et al.
CLINICAL CANCER RESEARCH (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Graft-versus-host disease
James L. M. Ferrara et al.
LANCET (2009)
The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress
Luke A. J. O'Neill
IMMUNOLOGICAL REVIEWS (2008)
The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Anna van Rhenen et al.
BLOOD (2007)
Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components
Constantinos Brikos et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Naoki Hosen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
mRNA expression of MAGE-A3 gene in leukemia cells
A. Martinez et al.
LEUKEMIA RESEARCH (2007)
Targeting of CD44 eradicates human acute myeloid leukemic stem cells
Liqing Jin et al.
NATURE MEDICINE (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients
G Perea et al.
LEUKEMIA RESEARCH (2005)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Myeloablative conditioning regimens for AML allografts: 30 years later
V Gupta et al.
BONE MARROW TRANSPLANTATION (2003)
分享论文
